ISCNF Company Profile and Key Details

The stock is currently trading near its 52-week low $0.00 and $0.00. With a market capitalization of about $1.76 thousand, Isracann Biosciences Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.19). Key stats such as the average daily volume over the past year has been around 43.00 thousand shares, trading with heavier-than-usual volume. Headquartered in Vancouver, BC, Isracann Biosciences Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Ajay Singh Kaila, the company employs approximately 0 people and listed since December 15, 2017. Isracann Biosciences Inc., operating with its subsidiary companies, focuses on the growth and supply of medical-grade cannabis throughout Israel.

Average 10-day trading volume of 5.15 thousand shares is below the 3-month average of 8.13 thousand, indicating normal recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Our AI price prediction model suggests that Isracann Biosciences Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Isracann Biosciences Inc. trading at a premium to the broader market with a P/E of -0.0.

Isracann Biosciences Inc. trades at a P/E ratio of -0.0, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.01 suggesting the stock is closer to book value. The P/FCF stands at -0.0, also above market averages.